Avalyn Pharma develops inhaled therapies targeting rare respiratory diseases, specifically pulmonary fibrosis and interstitial lung diseases, for patients and their care partners.
1 source
The Goodwin page is dated July 23, 2025, while it links to Avalyn’s July 22 press release; the listed announcement date follows the dated source provided.
Published by hand (goodwinlaw.com): "The Life Sciences team advised Avalyn Pharma Inc. on the closing of an oversubscribed $100 million Series D financing.": biggest-rounds completeness (K): the round's own page (company, lead investor or trade press) states it
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series D [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2025-07-23 | SR One, Suvretta Capital Management | No recent discussion |
1 source [ VERIFIED ] read against 1 source The Goodwin page is dated July 23, 2025, while it links to Avalyn’s July 22 press release; the listed announcement date follows the dated source provided. Published by hand (goodwinlaw.com): "The Life Sciences team advised Avalyn Pharma Inc. on the closing of an oversubscribed $100 million Series D financing.": biggest-rounds completeness (K): the round's own page (company, lead investor or trade press) states it | ||||